What are the uses of Binimetinib?

Binimetinib is an inhibitor with mitogen-activated protein kinase kinase (MEK). The drug is used in patients with unresectable or metastatic melanoma with BRAF V600E or V600.

Binimetinib also known by the common name Mektovi or ARRY-162. Used in combination with encorafenib to treat patients with unresectable or multiple metastatic melanoma with BRAF V600K, V600E mutations. Binimetinib works by stopping the growth and spread of cancer cells in the body.

Each tablet has a strength of 15 mg.
For patients with melanoma: Indicated in combination with Encorafenib with a general dose of 45 mg, used twice a day until disease progression. In case Encorafenib cannot be used, Binimetinib can be used instead.
However, the dose needs to be adjusted to suit each patient's condition and side effects occur during treatment, reduce the dose to 30 mg for the first dose, used twice a day. In cases where the patient's body cannot tolerate the dose of 30mg / day, the drug can be stopped.
Specific dosage is as follows:
Venous thromboembolism: The patient will stop using the drug if it improves to grade 0-1, continue taking it at a reduced dose. If the condition does not improve, it should be stopped permanently. Interstitial lung disease: If the disease is grade 2, the patient should stop taking the drug for up to 4 weeks if it improves to grade 0-1, continue at a reduced dose. If the disease does not progress, stop using the drug permanently. Hepatotoxicity: Maintain usual dose of Binimetinib if disease does not improve within 2 weeks, stop dose until improvement to grade 0-1. Hepatic impairment: Dosage is 30 mg orally twice a day.

In the COLUMBUS trial, approximately 6% of patients receiving binimetinib in combination with encorafenib developed venous thrombosis and 3.1% of patients developed pulmonary embolism. For patients with BRAF mutation-positive melanoma following administration of binimetinib with encorafenib (n = 690), approximately 0.3% of patients developed interstitial lung disease, including pneumonia. When combining Binimetinib with Encorafenib causes hepatotoxicity. Therefore, it is necessary to have liver tests before using the drug and during treatment to monitor. When using Binimetinib with Encorafenib, rhabdomyolysis syndrome - This is a clinical and biological syndrome that destroys skeletal muscle cells. Therefore, patients need to monitor CPK and creatinine levels before starting treatment and during treatment. Your doctor will monitor these numbers to make a decision whether to continue or stop taking the medication based on the severity of the side effects. Hemorrhage is one of the possible reactions when using encorafenib in combination with binimetinib, including hemorrhoidal, intracranial and rectal bleeding, and hematoma. Depending on the severity of these reactions, the doctor will either stop using the drug or continue it. According to the study, there will be 20% of patients with eye-related diseases including retinal detachment (8%), macular edema (6%). When using Binimetinib, users should have their eyes checked periodically to early detect diseases related to visual disturbances. Patients treated with Binimetinib in combination with Encorafenib may also develop cardiomyopathy with symptoms of left ventricular dysfunction.

When using Binimetinib, patients may experience some effects such as:
Dizziness, fever, bleeding, hyponatremia. Decreased white blood cell count, neutropenia, lymphopenia. Low lymphocyte levels, hypertension, colitis, conjunctivitis. Before using this medicine, you should tell your doctor if:
You have ever had heart disease, high blood pressure, liver or kidney disease, lung disease, eye problems, muscle disorders. Absolutely do not use Binimetinib if you are pregnant. If you are using Binimetinib, you should use safe contraception or need to abstain from becoming pregnant for at least 30 days after your last dose. For nursing women, there is currently no evidence that Binimetinib will be metabolized in breast milk, however because of the potential for adverse reactions in breastfed infants, women are advised by their doctors. Do not breast-feed during treatment with Binimetinib.

Drug interactions can change the effectiveness of the drug or increase the effect of side effects. Some drugs when used in combination with Binimetinib cause reactions such as:
Binimetinib serum concentrations may be increased when combined with Deferasirox, Peginterferon alfa-2b, Teriflunomide.... Metabolism. of Binimetinib can be increased when used with Nelfinavir, Zidovudine, Phenytoin, Lamotrigine, Oxcarbazepine, Efavirenz The article has provided information about what Binimetinib is, dosage and precautions for use. To ensure the safety of your health and maximize the effectiveness of treatment, you need to take the medicine exactly as directed by your doctor.